How Bayer is transforming healthcare through responsible AI adoption

In this April 2024 interview, Bayer's Head of Applied Imaging, Innovation and Data Enablement, Markus Blank, discusses how Bayer applies AI - guided by its "Health for all. Hunger for None" mission - across drug development and digital products. Bayer uses generative AI to create synthetic patient data for rare/new diseases (expanding scarce datasets while preserving privacy) and to assist with hypothesis generation and drafting regulatory documentation, which experts then review. Bayer chose Google Cloud, including Vertex AI, for its GxP- and HIPAA-compliant infrastructure; Blank says the resources freed up by these automations "can lead to more impactful discoveries that can transform patients' lives." No specific quantitative outcomes are given on the page.

Google supplies AI to pharma through several distinct lines — Gemini/Vertex AI as an enterprise platform, and AlphaFold-based drug design licensed commercially through Isomorphic Labs.

This sits in the Build stage of the AI use-case lifecycle: Named examples from the foundation-model labs and platforms pharma teams use to actually construct, train and generate the model or application.